RHBDD3 Antibody Summary
| Immunogen |
Antibody was raised against a 13 amino acid synthetic peptide from near the center of human RHBDD3. The immunogen is located within amino acids 170 – 220 of RHBDD3.
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
RHBDD3
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
||
| Control Peptide |
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for RHBDD3 Antibody
- C22orf3
- chromosome 22 open reading frame 3
- HS984G1A
- pituitary tumor apoptosis
- PTAG
- rhomboid domain containing 3
- rhomboid domain-containing protein 3
Background
The Rhomboid family of proteins is made up of several widely conserved polytopic membrane serine proteases that play roles in growth and development. RHBDD3 was initially identified as a novel pituitary tumor apoptosis gene (PTAG) whose expression was reduced in certain pituitary adenomas. Overexpression of RHBDD3 in AtT20 cells showed an increase in apoptotic activity and caspase activation in response to bromocriptine, and apoptosis-inducing dopamine D2 analog, suggesting that reactivation of RHBDD3 in tumors may be a therapeutically useful tool. Later experiments also showed that RHBDD3 expression is also reduced in several primary colorectal tumors, indicating that loss of RHBDD3 contributes to a blunted apoptotic response and probably predisposes cells towards malignant transformation.